Beam Therapeutics Inc
BEAM20.010USD
+0.130+0.65%
Handelsschluss 07/03, 13:00（ET）Kurse um 15 Minuten verzögert
2.01BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Beam Therapeutics Inc Unternehmen
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Unternehmensinformationen
BörsenkürzelBEAM
Name des UnternehmensBeam Therapeutics Inc
IPO-datumFeb 06, 2020
Gegründet am2017
CEOMr. John M. Evans
Anzahl der mitarbeiter483
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 06
Addresse238 Main Street
StadtCAMBRIDGE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02142
Telefon18573278775
Websitehttps://beamtx.com/
BörsenkürzelBEAM
IPO-datumFeb 06, 2020
Gegründet am2017
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
107.78K
-6.45%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
1.74K
-97.47%
Dr. Christine P. Bellon, Ph.D.
Dr. Christine P. Bellon, Ph.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Mr. Sravan K. Emany
Mr. Sravan K. Emany
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
--
--
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Independent Director
Independent Director
--
--
Ms. Christi Shaw
Ms. Christi Shaw
Independent Director
Independent Director
--
--
Dr. John Maraganore, Ph.D.
Dr. John Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Mark C. Fishman, M.D.
Dr. Mark C. Fishman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Graham K. Cooper
Mr. Graham K. Cooper
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
107.78K
-6.45%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
1.74K
-97.47%
Dr. Christine P. Bellon, Ph.D.
Dr. Christine P. Bellon, Ph.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Mr. Sravan K. Emany
Mr. Sravan K. Emany
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
--
--
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Independent Director
Independent Director
--
--
Umsatzaufteilung
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
7.47M
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Farallon Capital Management, L.L.C.
9.87%
The Vanguard Group, Inc.
8.80%
ARK Investment Management LLC
8.43%
Fidelity Management & Research Company LLC
7.56%
BlackRock Institutional Trust Company, N.A.
6.72%
Other
58.61%
Aktionäre
Aktionäre
Anteil
Farallon Capital Management, L.L.C.
9.87%
The Vanguard Group, Inc.
8.80%
ARK Investment Management LLC
8.43%
Fidelity Management & Research Company LLC
7.56%
BlackRock Institutional Trust Company, N.A.
6.72%
Other
58.61%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
38.62%
Investment Advisor/Hedge Fund
29.38%
Hedge Fund
20.30%
Venture Capital
4.83%
Research Firm
2.23%
Sovereign Wealth Fund
1.82%
Individual Investor
1.28%
Bank and Trust
0.46%
Pension Fund
0.31%
Other
0.77%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
531
99.92M
99.37%
+13.13M
2025Q1
562
100.13M
99.59%
+12.37M
2024Q4
542
80.18M
95.83%
-6.23M
2024Q3
539
78.60M
95.42%
-7.95M
2024Q2
538
78.23M
95.09%
-5.21M
2024Q1
550
76.09M
93.23%
-4.97M
2023Q4
549
75.48M
92.79%
-3.23M
2023Q3
554
74.84M
95.14%
-3.35M
2023Q2
566
72.06M
94.81%
-2.24M
2023Q1
583
68.81M
92.54%
-724.80K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Farallon Capital Management, L.L.C.
9.93M
9.87%
+1.69M
+20.50%
Mar 31, 2025
The Vanguard Group, Inc.
8.85M
8.8%
+1.24M
+16.36%
Mar 31, 2025
ARK Investment Management LLC
8.48M
8.43%
+1.41M
+19.98%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.60M
7.56%
+4.49M
+144.60%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.76M
6.72%
+838.01K
+14.15%
Mar 31, 2025
ARCH Venture Partners
4.54M
4.51%
--
--
Mar 31, 2025
Nikko Asset Management Co., Ltd.
4.27M
4.24%
+309.26K
+7.81%
Mar 31, 2025
State Street Global Advisors (US)
3.44M
3.42%
+362.74K
+11.79%
Mar 31, 2025
T. Rowe Price Associates, Inc.
2.94M
2.93%
+1.27M
+75.83%
Mar 31, 2025
Kynam Capital Management LP
2.52M
2.5%
+762.01K
+43.39%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Wed, Jul 2
Aktualisiert: Wed, Jul 2
Name
Anteil
ARK Genomic Revolution ETF
3.47%
Global X Genomics & Biotechnology ETF
1.9%
WisdomTree BioRevolution Fund
1.65%
ARK Innovation ETF
1.6%
Virtus LifeSci Biotech Clinical Trials ETF
0.65%
Franklin Genomic Advancements ETF
0.61%
SPDR S&P Biotech ETF
0.47%
NYLI Healthy Hearts ETF
0.33%
Direxion Daily S&P Biotech Bull 3X Shares
0.28%
iShares Health Innovation Active ETF
0.17%
Mehr Anzeigen
ARK Genomic Revolution ETF
Anteil3.47%
Global X Genomics & Biotechnology ETF
Anteil1.9%
WisdomTree BioRevolution Fund
Anteil1.65%
ARK Innovation ETF
Anteil1.6%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.65%
Franklin Genomic Advancements ETF
Anteil0.61%
SPDR S&P Biotech ETF
Anteil0.47%
NYLI Healthy Hearts ETF
Anteil0.33%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.28%
iShares Health Innovation Active ETF
Anteil0.17%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
